Oncology Institute (TOI) Earnings Transcript

The Oncology Institute reported 2025 revenue of $502.7M (up 27.8% YoY) and Q4 revenue of $142.0M (up 41.6% YoY), and delivered its first positive adjusted EBITDA quarter at $147K. Management reaffirmed 2026 guidance: revenue $630–650M, capitated revenue ~$150M, gross profit $97–107M, adjusted EBITDA $0–9M and free cash flow -$15M to $5M; pharmacy revenue was $269.2M (+49.6%) with a 2026 pharmacy run rate modeled at ~$27M/month. Operationally TOI added 9 capitated contracts (~260k lives), has ~70k delegated lives with Elevance in Florida (a $50M annualized run rate), expects ~$2M SG&A savings from AI, ended the year with $33.6M cash and paid down $24M on a convertible preferred note. Management flagged near-term seasonality risk with Q1 adjusted EBITDA loss (-$3M to -$1M) and expects the Inflation Reduction Act impact on IMBRUVICA to be minor (<1% of pharmacy revenue/gross margin).

Analysis

The company has built optionality: control over prescribing behavior (attachment) plus delegated population contracts creates a high-leverage asset because each incremental captive encounter compounds pharmacy capture and utilization-management upside. That leverage is binary — small improvements in attachment or utilization management translate to outsized gross-profit expansion, while operational slippage during a lives ramp produces magnified MLR pressure for quarters.

Competitive dynamics favor vertically integrated solutions: payers under top-line stress will increasingly outsource oncology risk to partners that can guarantee utilization discipline and local access, creating a durable commercial channel for the company but also a strategic window for large health plans and national specialty pharmacies to acquire or replicate the model. Expect payers to compress physician reimbursement but pay up for delegated partners who can credibly lower downstream drug and site-of-care spend, which makes strategic partnerships (or M&A) the most likely consolidation pathway.

Key operational risks are timing and liquidity. The cadence mismatch between drug price changes/reimbursement lags and contractual PMPM economics can produce sequential EBITDA swings; similarly, near-term cash burn during aggressive network onboarding is the primary tail risk and the likeliest catalyst for capital raising or convertible dilution. Conversely, AI-driven automation and procurement scale are scalable margin levers: initial SG&A gains are low absolute dollars today but compound as RCM/prior-auth automation reaches network-wide adoption.

Near-term catalysts to monitor are: (1) the mid-year ramp trajectory for delegated lives (quantifiable MLR inflection), (2) quarter-over-quarter pharmacy gross-margin sustainment post-IRA pass-throughs, and (3) any payer expansion deals or strategic distribution agreements. A successful sequence of those three would justify a re-rating; failure on two of three (especially liquidity indicators) is the simplest path to downside.

Key Decisions for Investors

• Long TOIIW equity (size 2–3% portfolio) with a 6–12 month horizon to capture capitation and pharmacy attach multiple expansion. Take profits if implied enterprise multiple expands by 30–50%; cut 50% if Q1 adjusted EBITDA misses the mid-point of guidance by >$2m or company signals an equity raise/dilution plan.
• Buy TOIIW 12–18 month LEAP call options (preferably in-the-money to reduce theta) as a leveraged alternative to stock to limit downside to premium while participating in upside from capitation ramp and pharmacy margin improvement. Target 2.5x return; stop if cash-flow guidance deteriorates materially or pharmacy gross margin contracts for two consecutive quarters.
• Small, tactical long HUM position or 9–15 month call spread (HUM) to play payor demand for delegated oncology capabilities. Rationale: insurers that secure scalable delegated partners extract outsized savings; hedge with a 25–30% stop if MA rate pressure materially widens or Humana issues adverse commentary on delegated model economics.
• Buy tail protection on TOIIW (3–6 month put or put spread sized 10–15% of the long exposure) to hedge execution and liquidity risk around the mid-2026 ramp; this keeps upside exposure while limiting drawdown from a surprise MLR deterioration or an equity raise.